Get started
Author

Panagiotis Malandrakis

Observed names: Malandrakis, Panagiotis, P Malandrakis, P. Malandrakis
Observed institutions: National and Kapodistrian University of Athens, Rigshospitalet, Alexandra Hospital, Karl Landsteiner University of Health Sciences, University of Cincinnati, Fuzhou University, University of Cincinnati Medical Center
ORCID: 0000-0002-4673-171X
Observed ORCID: 0000-0002-4673-171X
OpenAlex ID: A5059359090
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
2021 · Evangelos Terpos, Maria Gavriatopoulou, et al. · Blood Cancer Journal · 123
PDF
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
2021 · Maria Gavriatopoulou, Evangelos Terpos, et al. · Blood Advances · 42
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
2022 · Evangelos Terpos, Maria Gavriatopoulou, et al. · Blood · 36
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
2021 · Maria Gavriatopoulou, Evangelos Terpos, et al. · Clinical and Experimental Medicine · 36
PDF
Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance
2020 · Efstathios Kastritis, Foteini Theodorakakou, et al. · British Journal of Haematology · 36
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
2022 · Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, et al. · HemaSphere · 34
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma
2021 · Aristea-Maria Papanota, Paraskevi Karousi, et al. · International Journal of Molecular Sciences · 34
PDF
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
2020 · Konstantinos Papadimitriou, Nikolaos Tsakirakis, et al. · Cancers · 33
PDF
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications
2022 · Efstathios Kastritis, Magdalini Migkou, et al. · American Journal of Hematology · 32
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
2020 · Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, et al. · HemaSphere · 32
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
2025 · Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, et al. · American Journal of Hematology · 31
PDF
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome
2021 · Maria-Alexandra Papadimitriou, Aristea-Maria Papanota, et al. · British Journal of Cancer · 31
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
2021 · Evangelos Terpos, Marianna Politou, et al. · Vaccines · 29
PDF
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
2021 · Aristea-Maria Papanota, Panagiotis Tsiakanikas, et al. · Cancers · 28
PDF
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
2020 · Maria Gavriatopoulou, Andriani Βoultadaki, et al. · Blood Cancer Journal · 28
PDF
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
2022 · Evangelos Terpos, Vangelis Karalis, et al. · Biomedicines · 27
PDF
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma
2025 · Evangelos Terpos, Panagiotis Malandrakis, et al. · Blood · 26
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
2021 · Evangelos Terpos, Vangelis Karalis, et al. · Life · 26
PDF
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation
2023 · Evangelos Eleutherakis Papaiakovou, Evangelos Terpos, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 25
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
2022 · Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al. · Cancers · 24
PDF
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More
2022 · Ioannis V. Kostopoulos, Ioannis Ntanasis-Stathopoulos, et al. · Journal of Clinical Oncology · 22
PDF
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
2020 · Maria Gavriatopoulou, Evangelos Terpos, et al. · Blood Cancer Journal · 22
PDF
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
2021 · Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, et al. · Cancers · 21
PDF
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
2024 · Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, et al. · American Journal of Hematology · 19
PDF
XBB .1.5 neutralizing antibodies upon bivalent COVID ‐19 vaccination are similar to XBB but lower than BQ .1.1
2023 · Santhi Devasundaram, Evangelos Terpos, et al. · American Journal of Hematology · 18
PDF
Works count: 270
Citation count: 1,404
H-index: 22
I10-index: 46
Year
Topic
Type